DepemokimabasthmaGSKNCT04719832NCT04718103St George's Respiratory Questionnaire
… in patients on medium- vs high-dose ICS (figure 1).Conclusions Depemokimab reduces exacerbations in patfients with asthma across baseline …
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 290 of 2459CRSwNPCRSwNP-relatedOCSAdelphi Real World CRS Disease Specific Programme TMbiologicsbiologics
…This cross-sectional study emphasised the persistent OCS use in CRSwNP management, even as biologics are emerging as an alternative tr…
AsthmaSABAformoterol
…ced vital capacity, ACT – Asthma Control Test, cACT – childhood Asthma Control Test, N/A – not applicableDiscussion CYP prescribed MAR…
DIPNECHDiffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)PNEC
…ction. Disrupting this interaction may be a novel treatment for DIPNECH.…
Fibulin-3Scottish National MDTpleural mesotheliomaTsimimmediate treatmentScottish MDTJTO 2021
…ermediate-risk cases in the validated 3-group model by baseline Fibulin-3, generating the Glasgow Mesothelioma Score (GMS).Results Six in…
PH-LDPH-ILDPulmonary Hypertension
…16), respectively. During the first-year of follow-up, incident PH-LD and PH-ILD patients had a mean (95%CI) 3.46 (3.40–3.51) and 2.9…
chronic obstructive pulmonary diseaseCOPDCOPD-AFatrial fibrillationtargeted interventions
…hile arrhythmias are recognized as potential causes of death in chronic obstructive pulmonary disease (COPD) patients. However, temporal trends in arrhythmia-related…
mepolizumabT2 high SAGSKT2 high severe asthmaNCT05144087
…llected by bronchoscopy at baseline (T0) and 6 months (T6) post mepolizumab treatment ( NCT05144087, GSK funded, investigator led study). F…
depressionhypertensiondiabetesClinical Commissioning Groupearly treatmentchronic conditions
…stand the reasons for little progress over the past decade. For depression, strategies to increase early diagnosis should prioritise depri…
99.4%
RosuvastatinaspirinRosuelastase-induced aneurysmsASAthromboembolic complications
…omography), and histological/MPM strut coverage were evaluated. Rosuvastatin serum concentration was correlated with endothelial cell covera…
aspirin-clopidogrelaspirin-ticagrelorsCAStransient ischaemic attackminor stroke
…es in the aspirin-ticagrelor group and 222 cases (7.76%) in the aspirin-clopidogrel group (HR, 0.70; 95% CI, 0.57 to 0.86; p=0.0006). The treatment…